Athanor Capital’s Heron Therapeutics HRTX Stock Holding History

Athanor Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,885	Closed	-$400K	–	921
2020 Q4	$400K	Sell	18,885 -42,435	-69%	-$738K	0.01%	516
2020 Q3	$909K	Buy	61,320 +37,078	+153%	+$579K	0.03%	256
2020 Q2	$357K	Buy	+24,242	New	+$398K	0.02%	372
2018 Q2	–	Sell	-35,000	Closed	-$966K	–	53
2018 Q1	$966K	Buy	+35,000	New	+$794K	0.45%	29

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Athanor Capital's HRTX Position: Q1 2021 in Review

Athanor Capital sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 18,885 shares — an estimated $400K sold.

Athanor Capital first reported a position in HRTX in Q1 2018 and held it in 4 quarters. The position peaked at $966K in Q1 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Athanor Capital reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 18,885 Heron Therapeutics shares in Q1 2021, an estimated $400K.
Athanor Capital first reported a position in Heron Therapeutics in Q1 2018 and held it in 4 quarters.
Athanor Capital's Heron Therapeutics position peaked at $966K in Q1 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.